KR20230117403A - 피투시란을 이용한 혈우병의 치료 - Google Patents

피투시란을 이용한 혈우병의 치료 Download PDF

Info

Publication number
KR20230117403A
KR20230117403A KR1020237022579A KR20237022579A KR20230117403A KR 20230117403 A KR20230117403 A KR 20230117403A KR 1020237022579 A KR1020237022579 A KR 1020237022579A KR 20237022579 A KR20237022579 A KR 20237022579A KR 20230117403 A KR20230117403 A KR 20230117403A
Authority
KR
South Korea
Prior art keywords
patient
pitusiran
level
optionally
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022579A
Other languages
English (en)
Korean (ko)
Inventor
스테이시 폴로스키
샤우나 앤더슨
프래틱 알. 바군드
웨 추이
사지다 이끄발
바이송 메이
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20230117403A publication Critical patent/KR20230117403A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237022579A 2020-12-06 2021-12-06 피투시란을 이용한 혈우병의 치료 Pending KR20230117403A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063121973P 2020-12-06 2020-12-06
US63/121,973 2020-12-06
US202163272629P 2021-10-27 2021-10-27
US63/272,629 2021-10-27
US202163275344P 2021-11-03 2021-11-03
US63/275,344 2021-11-03
PCT/US2021/062078 WO2022120292A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Publications (1)

Publication Number Publication Date
KR20230117403A true KR20230117403A (ko) 2023-08-08

Family

ID=80112089

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022579A Pending KR20230117403A (ko) 2020-12-06 2021-12-06 피투시란을 이용한 혈우병의 치료

Country Status (10)

Country Link
US (1) US20240027478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552554A (cg-RX-API-DMAC7.html)
KR (1) KR20230117403A (cg-RX-API-DMAC7.html)
AU (1) AU2021391951A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204344A1 (cg-RX-API-DMAC7.html)
IL (1) IL303452A (cg-RX-API-DMAC7.html)
MX (1) MX2023006651A (cg-RX-API-DMAC7.html)
TW (1) TW202237151A (cg-RX-API-DMAC7.html)
WO (1) WO2022120292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258425A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
EP4612687A1 (en) 2022-11-02 2025-09-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin
TW202525306A (zh) * 2023-09-15 2025-07-01 美商健臻公司 用非妥西蘭(fitusiran)治療a型血友病
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Also Published As

Publication number Publication date
TW202237151A (zh) 2022-10-01
EP4255566A1 (en) 2023-10-11
JP2023552554A (ja) 2023-12-18
US20240027478A1 (en) 2024-01-25
AU2021391951A1 (en) 2023-07-20
IL303452A (en) 2023-08-01
AU2021391951A9 (en) 2024-05-02
MX2023006651A (es) 2023-08-02
WO2022120292A1 (en) 2022-06-09
CA3204344A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP2023552554A (ja) フィツシランを用いた血友病の処置
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
JP2020002182A (ja) 第ix因子ポリペプチド製剤
KR20230027277A (ko) 혈우병을 치료하기 위한 방법 및 조성물
TW202417014A (zh) 於小兒患者中以非妥西蘭治療血友病
KR20250024800A (ko) A형 및 b형 혈우병의 치료를 위한 피투시란
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
KR20190111912A (ko) 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
CN116635040A (zh) 用非妥西兰治疗血友病
HK40056298A (en) Modified factor vii polypeptides for subcutaneous administration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230704

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241206

Comment text: Request for Examination of Application